TICKERNERD
Menu
GMEDGMEDHealthcare · Medical Devices

GMED Stock Forecast: Globus Medical, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$86
−0.05% on the day

The 15 Wall Street analysts covering Globus Medical, Inc. hold a median 12-month price target of $100 — +16.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 15 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$11.5B
Ticker Nerd rank
96 / 100
Median analyst target
$100
Analysts covering
15
Total return, dividends reinvested
1W
+4.3%
1M
+13.3%
YTD
−1.6%
1Y
+43.1%
From 52W high
−11.3%
From 52W low
+55.9%
$55
$97
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

GMED stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Globus Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
96 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
97
Value
94
Revisions
91
Volatility
82
Growth
74
Momentum
71
Issuance
66
Accruals
55
Size
15

Quality (97): The business earns solid, repeatable profits on what it owns.

Accruals (55): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (15): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

GMED stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GMED, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$80$100$120Oct 25Jan 26Apr 26Jul 26GMEDHigh $125Median $100Low $84

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says15 analysts
10 Buy5 Hold0 Sell
Low $84Median $100High $125

The green dot is the last close — the median target sits +16.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
7 Aug 2026Wells FargoMaintainsOverweight$103 → $99
28 July 2026UBSInitiatesNeutral—
28 July 2026UBSInitiatesNeutral$82
16 July 2026Truist SecuritiesMaintainsBuy$115 → $100
16 July 2026Truist SecuritiesMaintainsBuy—
13 July 2026RBC CapitalMaintainsOutperform$120 → $115
13 July 2026RBC CapitalMaintainsOutperform—
9 July 2026BMO CapitalInitiatesOutperform—
8 July 2026StifelMaintainsHold$95 → $80
8 July 2026StifelMaintainsHold—
15 June 2026Piper SandlerMaintainsOverweight—
8 May 2026NeedhamMaintainsBuy—
8 May 2026RBC CapitalMaintainsOutperform—
8 May 2026Wells FargoMaintainsOverweight—
26 Feb 2026Wells FargoMaintainsOverweight—
25 Feb 2026BarclaysMaintainsOverweight—
25 Feb 2026NeedhamMaintainsBuy—
30 Jan 2026NeedhamUpgradeBuy—
9 Jan 2026Canaccord GenuityMaintainsBuy—
8 Jan 2026Piper SandlerReiteratesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GMED appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

GMED analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+5.6%
Analysts raising
14
Analysts cutting
0
Fundamentals

Globus Medical, Inc. (GMED) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
22.0×

Cheaper than 36% of US stocks

Price / sales
3.7×

Cheaper than 35% of US stocks

Price / book
2.5×

Cheaper than 41% of US stocks

EV / EBITDA
10.9×

Cheaper than 36% of US stocks

Growth & margins
Revenue growth (YoY)
5.9%

Higher than 41% of US stocks

Earnings growth (YoY)
−25.3%

Higher than 17% of US stocks

Gross margin
69.4%

Higher than 82% of US stocks

Operating margin
24.8%

Higher than 84% of US stocks

Net margin
17.0%

Higher than 80% of US stocks

Returns & dividend
Return on equity
11.8%

Higher than 68% of US stocks

Return on assets
8.7%

Higher than 90% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

GMED vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
GMEDGlobus Medical, Inc.$11.5B
96
GKOSGlaukos Corp.$10.9B
90
PENPenumbra, Inc.$12.9B
75
PODDInsulet Corp.$9.9B
89
BIOBio-Rad Laboratories, Inc.$9.5B
90
BRKRBruker Corp.$8.8B
82
ZBHZimmer Biomet Holdings, Inc.$19.9B
91

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Globus Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GMED news & analysis

Globus Medical (GMED) Upgraded to Strong Buy: Here's Why

Zacks Investment Research · 11 Aug 2026positive

Zacks Investment Research upgraded Globus Medical (GMED) to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. The upgrade is noted as potentially driving the stock higher in the near term.

Why it matters — A GMED watcher would care because the upgrade signals increased optimism from a prominent research firm about the company's earnings outlook.

GMED vs. ITGR: Which Stock Is the Better Value Option?

Zacks Investment Research · 11 Aug 2026neutral

Zacks Investment Research published a comparison of Globus Medical (GMED) and Integer (ITGR), both in the Medical - Instruments sector, evaluating which stock may be more attractive to value investors. The piece poses the question without providing an answer in the excerpt.

Why it matters — A GMED watcher would care because the comparison highlights how the company is being evaluated against a direct sector peer from a value-investing perspective.

Globus Medical Q2 Earnings Call Highlights

MarketBeat · 8 Aug 2026positive

Globus Medical reported second-quarter 2026 revenue of $789.6 million, up 6% year over year, driven by growth in spine and trauma businesses. The company reaffirmed its full-year revenue outlook while raising its adjusted earnings forecast.

Why it matters — The earnings beat and upgraded profit forecast suggest improving operational efficiency and margin expansion at Globus Medical.

GMED Q2 Earnings Call Highlights Margin Gains and Revenue Caution

Zacks Investment Research · 7 Aug 2026neutral

Globus Medical raised its 2026 EPS guidance following second-quarter margin gains and spine segment growth, while keeping its sales outlook unchanged due to risks from Nevro and Enabling Technologies.

Why it matters — The update signals improved profitability from margin expansion but also highlights lingering revenue headwinds that could temper future top-line performance.

Globus Medical (GMED) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Investment Research · 7 Aug 2026neutral

Zacks coverage of Globus Medical's Q2 2026 earnings examines how key metrics compare against Wall Street estimates and year-ago figures, in addition to the top- and bottom-line results.

Why it matters — A GMED watcher would care because the article provides a detailed look at the company's underlying performance metrics versus analyst expectations for the June 2026 quarter.

FAQ

Frequently asked questions about GMED stock

What is the GMED stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Globus Medical, Inc. have a median 12-month price target of $100, with estimates ranging from $84 to $125. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GMED stock a buy right now?

Of the 15 analysts covering Globus Medical, Inc., 10 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Globus Medical, Inc. 96 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GMED?

As at 15 Aug 2026, Globus Medical, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (97 of 100).

Will GMED stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +16.4% from the last close, and Ticker Nerd's factor model ranks Globus Medical, Inc. 96 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GMED stock forecast for 2030?

No analyst covering Globus Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GMED are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $84 to $125 over the next 12 months.

How has GMED stock performed over the past year?

Globus Medical, Inc. returned +43.1% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Globus Medical, Inc. do?

Globus Medical Inc. is a leading global musculoskeletal technology company that develops and commercializes implantable devices, biologics, accessories, and surgical instruments for spinal, orthopedic trauma, neurosurgical, and joint reconstruction procedures.

What is the latest news on GMED?

The most recent item we track (Zacks Investment Research, 11 Aug 2026): "Globus Medical (GMED) Upgraded to Strong Buy: Here's Why". Zacks Investment Research upgraded Globus Medical (GMED) to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. The upgrade is noted as potentially driving the stock higher in the near term.

Company

About Globus Medical, Inc.

Globus Medical Inc. is a leading global musculoskeletal technology company that develops and commercializes implantable devices, biologics, accessories, and surgical instruments for spinal, orthopedic trauma, neurosurgical, and joint reconstruction procedures. The company focuses on solving unmet clinical needs through innovative solutions, including its comprehensive spine and orthopedic portfolios, regenerative biologics, and enabling technologies such as robotics, navigation systems, and the Excelsius™ platform. Globus Medical provides world-class education and clinical support via its Musculoskeletal Education and Research Center, offering training in cadaveric labs, research facilities with biomechanical testing, and peer-to-peer programs to advance patient outcomes. It emphasizes exceptional surgeon response, rapid product innovation through iterative design cycles, and collaboration with healthcare professionals to enhance surgical accuracy, minimize invasiveness, and improve care efficiency. Founded in 2003 and headquartered in Audubon, Pennsylvania, Globus Medical plays a vital role in the medical device industry by delivering technologies that promote healing for patients with musculoskeletal disorders.

CEO Mr. Keith W. Pfeil · 6,000 employees · United States · https://www.globusmedical.com